Skip to main content

Research Repository

Advanced Search

Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients

Abstract

Methotrexate (MTX) monotherapy is a common first treatment for rheumatoid arthritis (RA), but many patients do not respond adequately. In order to identify genetic predictors of response, we have combined data from two consortia to carry out a genome-wide study of response to MTX in 1424 early RA patients of European ancestry. Clinical endpoints were change from baseline to 6 months after starting treatment in swollen 28-joint count, tender 28-joint count, C-reactive protein and the overall 3-component disease activity score (DAS28). No single nucleotide polymorphism (SNP) reached genome-wide statistical significance for any outcome measure. The strongest evidence for association was with rs168201 in NRG3 (p?=?10-7 for change in DAS28). Some support was also seen for association with ZMIZ1, previously highlighted in a study of response to MTX in juvenile idiopathic arthritis. Follow-up in two smaller cohorts of 429 and 177 RA patients did not support these findings, although these cohorts were more heterogeneous.

Acceptance Date Feb 9, 2018
Publication Date May 25, 2018
Journal Pharmacogenomics Journal
Print ISSN 1470-269X
Publisher Nature Publishing Group
Pages 528-538
DOI https://doi.org/10.1038/s41397-018-0025-5
Publisher URL http://doi.org/10.1038/s41397-018-0025-5

Files

MTX GWAS Appendix II PAMERA Consortia.docx (18 Kb)
Document


MTX GWAS Appendix I MATURA Consortia.docx (18 Kb)
Document




MTX_GWAS final submitted version.docx (157 Kb)
Document


MTX_GWAS_SuppInfo_Revised approved changes.docx (145 Kb)
Document




MTX_GWAS_SuppTabs_Revision.xls (395 Kb)
Spreadsheet






Downloadable Citations